Re-establishing Significant Benefit: Biopharma Company Builds a Successful EU Orphan Drug Designation Strategy

Client Challenge

A rare disease biopharmaceutical company applied for EU Orphan Drug Designation (ODD) but did not initially receive a positive opinion. ODD, however, represented a critical milestone for the client, not only to formally recognize the value of the available data for patients, but also to strengthen the program’s attractiveness to potential investors.

The regulatory context required careful navigation. The completed Phase II study did not fully meet its primary endpoint; this prompted careful consideration of how the Committee for Orphan Medicinal Products (COMP) would assess the product’s ability to demonstrate significant benefit, a key requirement for ODD in the EU. The study outcome underscored the need for a refined regulatory strategy for resubmission.

The client, therefore, sought an experienced regulatory partner capable of combining deep scientific expertise with strategic regulatory insight to support a new ODD application. The objective was to develop a compelling, science-based rationale aligned with EU regulatory expectations while still consistent with the client’s overall development strategy.

The client selected the Alira Health Regulatory team based on its strong scientific background, deep knowledge of the rare disease landscape, and proven experience in interactions with EU regulators. Other key selection criteria included the team’s collaborative approach and ability to translate complex data into clear regulatory arguments.

Our Approach

The Alira Health Regulatory team focused on a central regulatory requirement for EU ODD: proof that “the medicinal product will be of significant benefit to those affected by the condition.” The team implemented a structured, stepwise strategy in close collaboration with the client.

ODD submission support

The client already had a well-defined strategic position for how to demonstrate significant benefit that reflected both the scientific context of the program and the client’s overall development strategy. The Alira Health Regulatory team worked closely with the client to translate this positioning into a clear, scientifically robust regulatory narrative, ensuring that the dossier was coherent, focused, and aligned with EU ODD requirements while fully respecting the client’s strategic intent.

Regulatory interaction support and response to COMP questions

The COMP requested further clarification regarding the rationale that supported significant benefit. In response, the Alira Health team then conducted a detailed analysis of the COMP assessment report and guided the client through a structured reassessment of the regulatory strategy. The team leveraged their regulatory insights and a deep understanding of COMP expectations to propose targeted adjustments to the scientific narrative that re-contextualized existing data. The goal was to more effectively address the committee’s concerns and better position the product within the EU treatment landscape. The team aligned the revised approach with the client and implemented it efficiently.

Preparation for oral explanation

When the COMP invited the client to prepare an oral explanation, Alira Health provided end-to-end support, including a detailed walkthrough of the process and strategic guidance on how to articulate clear, compelling scientific messages. The team prepared a carefully tailored presentation that the client submitted to the COMP in advance of the oral explanation.

Outcomes

The COMP issued a positive opinion granting EU ODD, without requiring the oral explanation, as a result of this regulatory strategy. The revised dossier and refined scientific positioning reflected strong alignment with COMP expectations, successfully addressed the committee’s concerns, and convinced a majority of COMP members of the product’s significant benefit.

With Alira Health’s support, the client was able to refine its regulatory approach and secure ODD, significantly enhancing the product’s value and investor appeal. The process also strengthened the client’s credibility with investors and board members, established a foundation of trust with EU regulators, and provided renewed clarity and confidence around the regulatory strategy.

The positive COMP opinion represented a vital step toward making the product available to patients with a rare disease.

Key Success Factors

The Alira Health Regulatory team drove the success of this engagement with deep scientific expertise, rare disease knowledge, and firsthand understanding of COMP expectations. The team fully grasped the disease mechanism and product mode of action; this enabled the development of scientifically rigorous and credible, regulator-appropriate arguments. The team’s insight into the regulatory mindset was equally important. The team aligned the data with the way the COMP evaluates ODD applications by refining the scientific narrative and strengthening the efficacy-based justification for significant benefit.

Agility, responsiveness, and close collaboration characterized the engagement. Alira Health acted as a true strategic partner through constructive challenges, transparent communication, and mutual trust, helping the client refine its approach while preserving scientific integrity.